Sensus Healthcare (NASDAQ:SRTS) Posts Earnings Results, Misses Estimates By $0.04 EPS

Sensus Healthcare (NASDAQ:SRTS) announced its quarterly earnings results on Thursday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04), Zacks reports. The firm had revenue of $3.39 million for the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.

Here are the key takeaways from Sensus Healthcare’s conference call:

• Sensus says new dedicated CPT codes effective Jan 1, 2026 materially improve reimbursement — including about a 300% increase in the per‑fraction delivery code — and early EOBs show payers are processing claims, which management says is driving stronger physician interest and pipeline growth.
• Q1 revenue was $3.4 million versus $8.3 million a year ago primarily because there were no sales to the company’s historically largest customer; adjusted EBITDA was negative $4.2 million and net loss was $2.6 million, though management notes underlying growth when excluding that customer.
• Management is prioritizing recurring revenue through the Sensus Link software and the Fair Deal/rental program (18 active Fair Deal sites, 9 pending), and highlighted a reimbursable weekly radiation physics code (~$93.85/week) that can be monetized and shared with customers via Sensus Link.
• Commercial expansion initiatives — 14 systems shipped in Q1 (10 direct, 4 Fair Deal/rental), ~70% purchases of systems in the quarter, the launch of Sensus Healthcare Financial Services, and a stronger conference-driven pipeline — underpin management’s expectation of higher Q2/H2 revenue and a path to full‑year profitability.

Sensus Healthcare Stock Down 25.1%

Shares of NASDAQ:SRTS traded down $1.03 during midday trading on Friday, reaching $3.08. 665,134 shares of the company were exchanged, compared to its average volume of 84,977. The stock has a fifty day simple moving average of $4.14 and a two-hundred day simple moving average of $4.16. Sensus Healthcare has a fifty-two week low of $2.82 and a fifty-two week high of $5.92. The firm has a market cap of $50.70 million, a PE ratio of -6.55 and a beta of 1.19.

Institutional Trading of Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $77,000. Jane Street Group LLC acquired a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $79,000. Ingalls & Snyder LLC acquired a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $219,000. State Street Corp increased its position in shares of Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after acquiring an additional 3,400 shares during the last quarter. Finally, Rothschild Wealth LLC acquired a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $500,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SRTS shares. Alliance Global Partners began coverage on shares of Sensus Healthcare in a research report on Friday, March 6th. They set a “buy” rating and a $7.50 price target on the stock. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday. Maxim Group dropped their price objective on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.88.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.